Robert Wasserman
Stock Analyst at Benchmark
(3.55)
# 1,028
Out of 5,048 analysts
111
Total ratings
50.94%
Success rate
5.08%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $49.04 | +12.15% | 7 | Nov 3, 2025 | |
| ITGR Integer Holdings | Downgrades: Hold | n/a | $67.22 | - | 12 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $68.76 | +30.89% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.58 | +157.51% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $61.88 | +21.20% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.71 | +123.55% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.49 | +302.68% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $33.02 | +6.01% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $5.09 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $27.03 | +10.99% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $2.55 | +214.34% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $5.11 | -2.17% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $10.31 | +16.45% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.17 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $147.94 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.85 | +3.90% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.33 | +1,130.39% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.49 | +2,912.05% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $214.45 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $566.42 | +2.40% | 1 | Jul 16, 2021 |
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $49.04
Upside: +12.15%
Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $67.22
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $68.76
Upside: +30.89%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.58
Upside: +157.51%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $61.88
Upside: +21.20%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.71
Upside: +123.55%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.49
Upside: +302.68%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $33.02
Upside: +6.01%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.09
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $27.03
Upside: +10.99%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.55
Upside: +214.34%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $5.11
Upside: -2.17%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $10.31
Upside: +16.45%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.17
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $147.94
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.85
Upside: +3.90%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.33
Upside: +1,130.39%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.49
Upside: +2,912.05%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $214.45
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $566.42
Upside: +2.40%